Soluna Reports Q2’25 Results Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer
Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers,…
Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer
Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers,…
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL,…
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL,…
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Humacyte to Present at the Jefferies Healthcare Conference
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq:…
Humacyte to Present at the Jefferies Healthcare Conference
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq:…
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or…
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or…
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC…
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC…
Ocular Therapeutixâ„¢ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company…
Ocular Therapeutixâ„¢ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company…
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…